Citi says buy the dip in Eli Lilly ahead of Alzheimer's drug launch

Eli Lilly Pharmaceutical company logo
SOPA Images | LightRocket | Getty Images

The recent pullback in Eli Lilly's stock provides an attractive buying opportunity ahead of the company's Alzheimer's drug launch, Citi said.

More In Street Calls

CNBC ProEtsy shares will remain under pressure even after 60% pullback this year, Needham says
CNBC ProNeedham upgrades Chewy, says shares can rally more than 40% because the pet space is defensive
CNBC ProGoldman Sachs says buy AutoZone, a 'defensively positioned' stock to weather inflation